Host Hotels & Resorts Inc. Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? Host Hotels & Resorts Inc. Common Stock trades at $22.56 (market cap $15.44B), while State Street SPDR S&P Biotech ETF trades at $154.31 (market cap $10.11B). The key difference: Host Hotels & Resorts Inc. Common Stock is the larger of the two by market cap, and Host Hotels & Resorts Inc. Common Stock pays a 3.55% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Host Hotels & Resorts Inc. Common Stock for 0 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| HST | XBI | |
|---|---|---|
Market Cap | $15.44B | $10.11B |
Volume | 6,250,070 | 12,903,266 |
Sector | Real Estate | Broad Market / Factor |
52-Week High | $25.54 | $169.55 |
52-Week Low | $15.82 | $104.99 |
Typical Hold Time | 0 Days | 37 Days |
Enterprise Value | $19.13B | — |
Dividend Yield | 3.55% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Host Hotels & Resorts is a real estate investment trust that owns luxury and upscale hotel properties. Its portfolio includes hotels operated under major global brands.
Read more on HST →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →